HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane (NCT05424835) | Jiangsu HengRui Medicine Co., Ltd. | 2022-08-04 |
Track HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane automatically
Every clearance here is in the API, with alerts when new ones post.